Key Takeaways
- • Seismic Therapeutic closed a $121 million Series B funding round led by Bessemer Venture Partners, bringing total capital raised to $222 million and establishing the company as a significant player in machine learning-driven drug discovery.
- • The financing includes participation from strategic new investors Amgen Ventures and Codon Capital, alongside existing backers, signaling institutional confidence in the company's AI-immunology platform and pipeline trajectory.
- • Proceeds will advance two lead programs through Phase 1 proof-of-mechanism trials: S-1117 (pan-IgG protease sculpting enzyme) and S-4321 (PD-1 agonist targeting autoimmune diseases), with additional capital directed toward pipeline expansion and platform development.
- • Seismic's proprietary IMPACT platform integrates machine learning to parallelize drug discovery components, enabling accelerated protein design and analysis—a differentiated approach to immunology therapeutics that addresses unmet needs in autoimmune disease treatment.
- • Andrew Hedin from Bessemer Venture Partners will join Seismic's board, reflecting standard syndicate governance practices and indicating lead investor commitment to operational oversight during clinical advancement.
Summary
Seismic Therapeutic, a Boston-based biotechnology company focused on machine learning-enabled immunology drug discovery, has successfully closed a $121 million Series B financing round. The round was led by Bessemer Venture Partners and included participation from new institutional investors Amgen Ventures and Codon Capital, along with contributions from existing shareholders. The capital raise brings Seismic's cumulative funding to $222 million, positioning the company for advanced clinical development and pipeline expansion.
The funding will be deployed strategically across clinical advancement and platform development. Primary allocation will support advancement of two lead candidates—S-1117, a pan-IgG protease sculpting enzyme, and S-4321, a PD-1 agonist:Fc gamma receptor IIb selective dual-cell bidirectional antibody—through Phase 1 proof-of-mechanism trials. These programs target autoimmune disease indications with significant unmet medical needs. Beyond lead programs, capital will fund broader pipeline expansion and continued development of Seismic's proprietary IMPACT platform, which integrates machine learning to parallelize and accelerate multiple components of drug discovery workflows.
Seismic's differentiated approach combines machine learning capabilities with deep biological and drug development expertise to optimize immunology therapeutics. The IMPACT platform's core utility lies in its ability to accelerate protein design and analysis by leveraging computational methods to inform and validate therapeutic candidates. According to Jo Viney, the company's Founder, President, and CEO, the timing is optimal to harness machine learning advances for next-generation biologics development. Andrew Hedin from lead investor Bessemer Venture Partners will join Seismic's board of directors as part of the financing agreement, a standard governance mechanism reflecting investor involvement in high-stage biotechnology investments.
This financing occurs within a competitive landscape of AI-driven drug discovery, where institutional capital continues to flow toward companies demonstrating tangible clinical validation pathways. Amgen Ventures' participation signals confidence from a large pharmaceutical entity, potentially indicating strategic interest in emerging immunology approaches or partnership optionality.
The funding will be deployed strategically across clinical advancement and platform development. Primary allocation will support advancement of two lead candidates—S-1117, a pan-IgG protease sculpting enzyme, and S-4321, a PD-1 agonist:Fc gamma receptor IIb selective dual-cell bidirectional antibody—through Phase 1 proof-of-mechanism trials. These programs target autoimmune disease indications with significant unmet medical needs. Beyond lead programs, capital will fund broader pipeline expansion and continued development of Seismic's proprietary IMPACT platform, which integrates machine learning to parallelize and accelerate multiple components of drug discovery workflows.
Seismic's differentiated approach combines machine learning capabilities with deep biological and drug development expertise to optimize immunology therapeutics. The IMPACT platform's core utility lies in its ability to accelerate protein design and analysis by leveraging computational methods to inform and validate therapeutic candidates. According to Jo Viney, the company's Founder, President, and CEO, the timing is optimal to harness machine learning advances for next-generation biologics development. Andrew Hedin from lead investor Bessemer Venture Partners will join Seismic's board of directors as part of the financing agreement, a standard governance mechanism reflecting investor involvement in high-stage biotechnology investments.
This financing occurs within a competitive landscape of AI-driven drug discovery, where institutional capital continues to flow toward companies demonstrating tangible clinical validation pathways. Amgen Ventures' participation signals confidence from a large pharmaceutical entity, potentially indicating strategic interest in emerging immunology approaches or partnership optionality.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.